India may have to lower the import duty on pharmaceuticals for Peru in the discussions on the proposed free trade agreement (FTA) with the South American country.
The present Indian government has relaunched the talks with Israel. Israel wishes to conduct talks on regular basis to conclude the deal at the earliest. Indian patent system and pharmaceutical related issues have been the reasons why the deal couldn’t progress.
India’s position in the RCEP is the most protectionist among all the member nations. India has been resisting demands from Korea & Japan on intellectual property clauses, and other nations on opening up markets.
If the trade equation between India and Peru is in imbalance it would be causing more harm than benefit to India.
Negotiations are now nearing completion and there are increasing concerns among public health advocates, patient and consumer organisations, and other stakeholders, both in Europe and the Americas.
EU-MERCOSUR trade negotiations must not impose TRIPS Plus provisions on protection and enforcement of intellectual property rights.
The adoption of the measures proposed by the EU could put the sustainability of access to health policies in Brazil at risk, as they could sharply increase public expenditures on medicines.
The latest plan to get the controversial trade deal up and running involves freezing some of its controversial rules, including rules for biologic drugs, an expensive class of medicines often used to treat conditions such as cancer and rheumatoid arthritis.
As the TPP-11 meet to attempt to revive the TPP without the US, the research findings show how damaging the original medicine proposals would be.
India firm in opposing proposals that could hinder global access to affordable generic drugs
Healthcare watchers are calling on India to resist RCEP
Access to health products is non-negotiable; the Indian Government should reject the bullying tactics of the US based medical device industry.
RCEP negotiations should not restrict global access to affordable medicines and vaccines
The RCEP has hidden costs for people’s lives
RCEP will give multinational corporations unprecedented rights
Switzerland insists on intellectual property commitments beyond TRIPS.
Sanofi Aventis Ukraine LLC, part of Sanofi global pharmaceutical company, seeks to file a claim against Ukraine to the International Investment Arbitration.
The first ever final award on patents in international investment arbitration by ICSID in the case of Eli Lilly v. Canada has effectively cleared the way for raising future disputes by foreign IPR owners against domestic institutions which can result in stronger and robust IP protection regime.
The new regime has been implemented in order to meet Canada’s obligations under the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union
TPP 11 negotiators have agreed to suspend controversial clauses on medicine monopolies and some governments want to renegotiate other clauses, vindicating public interest group concerns